Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation

Abstract

Methods for the treatment of CNS disorders using combinations of muscarinic activators and inhibitors, and medicaments comprising muscarinic activators and inhibitors.

1 . A method of treating a central nervous system disorder comprising:
 administering to a patient a muscarinic Activator with a muscarinic Inhibitor, wherein the central nervous system disorder is selected from schizophrenia, Disorders Related To Schizophrenia, Muscarinic Disorder, Movement Disorder, Mood Disorder, Cognitive Disorder, Attention Disorder, and Addictive Disorder.   
     
     
         2 . A method of decreasing a side effect induced by a muscarinic Activator in a patient, comprising administering to the patient a muscarinic Inhibitor. 
     
     
         3 . The method according to  claim 1  or  claim 2 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of less than 149. 
     
     
         4 . The method according to  claim 1  or  claim 2 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 150. 
     
     
         5 . The method according to  claim 1  or  claim 2 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 200. 
     
     
         6 . The method according to  claim 1  or  claim 2 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 230. 
     
     
         7 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator is administered consecutively with the muscarinic Inhibitor. 
     
     
         8 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Inhibitor and the muscarinic Activator are administered simultaneously. 
     
     
         9 . The method according to  claim 1  or  claim 2 , wherein from 10 micrograms to 10 grams of the muscarinic Activator is administered. 
     
     
         10 . The method according to  claim 1  or  claim 2 , wherein from 1 milligram to 1 gram of the muscarinic Activator is administered. 
     
     
         11 . The method according to  claim 1  or  claim 2 , wherein from 10 micrograms to 10 grams of the muscarinic Inhibitor is administered. 
     
     
         12 . The method according to  claim 1  or  claim 2 , wherein from 1 milligram to 1 gram of the muscarinic Inhibitor is administered. 
     
     
         13 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator and the muscarinic Inhibitor are packaged in one dosage vehicle. 
     
     
         14 . The method of  claim 13 , wherein the dosage vehicle is selected from a tablet, troche, liquid, emulsion, suspension, drops, capsule, gel cap, cream, gel, ointment, foam, cream, aerosol, suppository, enema, and vaginal ring. 
     
     
         15 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator and the muscarinic Inhibitor are packaged in separate dosage vehicles independently selected from a tablet, troche, liquid, emulsion, suspension, drops, capsule, gel cap, cream, gel, ointment, foam, cream, aerosol, suppository, enema, and vaginal ring. 
     
     
         16 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator and the muscarinic Inhibitor are formulated in an immediate release formulation. 
     
     
         17 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator and the muscarinic Inhibitor are formulated in a controlled release formulation. 
     
     
         18 . The method according to  claim 1  or  claim 2 , wherein the muscarinic Activator and the muscarinic Inhibitor are administered in combination with a therapeutic agent. 
     
     
         19 . The method of  claim 18 , wherein the therapeutic agent is selected from an antipsychotic, an anxiolytic, an anti-depressant, a sedative, a tranquilizer, and combinations thereof. 
     
     
         20 . A medicament comprising a muscarinic Activator, a muscarinic Inhibitor, and a pharmaceutically acceptable carrier. 
     
     
         21 . The medicament of  claim 20 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of less than 149. 
     
     
         22 . The medicament of  claim 20 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 150. 
     
     
         23 . The medicament of  claim 20 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 200. 
     
     
         24 . The medicament of  claim 20 , wherein the combination of the muscarinic Activator and the muscarinic Inhibitor has a theta score of greater than 230. 
     
     
         25 . The medicament of  claim 20 , comprising from 10 micrograms to 10 grams of the muscarinic Activator. 
     
     
         26 . The medicament of  claim 20 , comprising from 1 milligram to 1 gram of the muscarinic Activator. 
     
     
         27 . The medicament of  claim 20 , comprising from 10 micrograms to 10 grams of the muscarinic Inhibitor. 
     
     
         28 . The medicament of  claim 20 , comprising from 1 milligram to 1 gram of the muscarinic Inhibitor. 
     
     
         29 . The medicament of  claim 20 , which is in the form of a tablet, troche, liquid, emulsion, suspension, drops, capsule, gel cap, cream, gel, ointment, foam, cream, aerosol, suppository, enema, or vaginal ring. 
     
     
         30 . The medicament of  claim 20 , which is formulated as an immediate release formulation. 
     
     
         31 . The medicament of  claim 20 , which is formulated as a controlled release formulation.